Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2016

Open Access 01-07-2016 | Review

The IL-1 cytokine family and its role in inflammation and fibrosis in the lung

Author: L. A. Borthwick

Published in: Seminars in Immunopathology | Issue 4/2016

Login to get access

Abstract

The IL-1 cytokine family comprises 11 members (7 ligands with agonist activity, 3 receptor antagonists and 1 anti-inflammatory cytokine) and is recognised as a key mediator of inflammation and fibrosis in multiple tissues including the lung. IL-1 targeted therapies have been successfully employed to treat a range of inflammatory conditions such as rheumatoid arthritis and gouty arthritis. This review will introduce the members of the IL-1 cytokine family, briefly discuss the cellular origins and cellular targets and provide an overview of the role of these molecules in inflammation and fibrosis in the lung.
Literature
1.
2.
Borthwick LA, Wynn TA, Fisher AJ (1832) Cytokine mediated tissue fibrosis. Biochim Biophys Acta 2013:1049–1060
3.
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653PubMedCrossRef
4.
Coward WR, Saini G, Jenkins G (2010) The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 4:367–388PubMedCrossRef
5.
6.
Menkin V (1943) Studies on the isolation of the factor responsible for tissue injury in inflammation. Science 97:165–167PubMedCrossRef
7.
Dinarello CA, Renfer L, Wolff SM (1977) Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A 74:4624–4627PubMedPubMedCentralCrossRef
8.
Rosenwasser LJ, Dinarello CA, Rosenthal AS (1979) Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med 150:709–714PubMedCrossRef
9.
Mizel SB, Oppenheim JJ, Rosentreich DL (1978) Characterization of lymphocyte-activating factor (LAF) produced by a macrophage cell line, P388D1. II. Biochemical characterization of LAF induced by activated T cells and LPS. J Immunol 120:1504–1508PubMed
10.
(1979) Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J Immunol 123:2928–2929
11.
Lomedico PT, Gubler U, Hellmann CP, Dukovich M, Giri JG, Pan YC et al (1984) Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 312:458–462PubMedCrossRef
12.
Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM et al (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 81:7907–7911PubMedPubMedCentralCrossRef
13.
Modi WS, Masuda A, Yamada M, Oppenheim JJ, Matsushima K, O’Brien SJ (1988) Chromosomal localization of the human interleukin 1 alpha (IL-1 alpha) gene. Genomics 2:310–314PubMedCrossRef
14.
Dower SK, Kronheim SR, Hopp TP, Cantrell M, Deeley M, Gillis S et al (1986) The cell surface receptors for interleukin-1 alpha and interleukin-1 beta are identical. Nature 324:266–268PubMedCrossRef
15.
Wessendorf JH, Garfinkel S, Zhan X, Brown S, Maciag T (1993) Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. J Biol Chem 268:22100–22104PubMed
16.
Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y et al (2004) The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 101:2434–2439PubMedPubMedCentralCrossRef
17.
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550PubMedCrossRef
18.
19.
Vareille M, Kieninger E, Edwards MR, Regamey N (2011) The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev 24:210–229PubMedPubMedCentralCrossRef
20.
Calderon-Garciduenas L, Osnaya N, Rodriguez-Alcaraz A, Villarreal-Calderon A (1997) DNA damage in nasal respiratory epithelium from children exposed to urban pollution. Environ Mol Mutagen 30:11–20PubMedCrossRef
21.
Rabinovici R, Neville LF, Abdullah F, Phillip DR, Vernick J, Fong KL et al (1995) Aspiration-induced lung injury: role of complement. Crit Care Med 23:1405–1411PubMedCrossRef
22.
Pauwels NS, Bracke KR, Dupont LL, Van Pottelberge GR, Provoost S, Vanden Berghe T et al (2011) Role of IL-1alpha and the Nlrp3/caspase-1/IL-1beta axis in cigarette smoke-induced pulmonary inflammation and COPD. Euro Respir J 38:1019–1028CrossRef
23.
24.
Aoshiba K, Nagai A (2003) Oxidative stress, cell death, and other damage to alveolar epithelial cells induced by cigarette smoke. Tob Induc Dis 1:219–226PubMedPubMedCentralCrossRef
25.
Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR et al (2010) Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A 107:2574–2579PubMedPubMedCentralCrossRef
26.
Luheshi NM, McColl BW, Brough D (2009) Nuclear retention of IL-1 alpha by necrotic cells: a mechanism to dampen sterile inflammation. Eur J Immunol 39:2973–2980PubMedPubMedCentralCrossRef
27.
Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13:851–856PubMedCrossRef
28.
Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E et al (2011) IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 187:4835–4843PubMedCrossRef
29.
Dagvadorj J, Shimada K, Chen S, Jones HD, Tumurkhuu G, Zhang W et al (2015) Lipopolysaccharide induces alveolar macrophage necrosis via CD14 and the P2X7 receptor leading to interleukin-1alpha release. Immunity 42:640–653PubMedPubMedCentralCrossRef
30.
Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, Couillin I et al (2010) Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci U S A 107:19449–19454PubMedPubMedCentralCrossRef
31.
Sung SS, Walters JA (1991) Increased cyclic AMP levels enhance IL-1 alpha and IL-1 beta mRNA expression and protein production in human myelomonocytic cell lines and monocytes. J Clin Invest 88:1915–1923PubMedPubMedCentralCrossRef
32.
Brody DT, Durum SK (1989) Membrane IL-1: IL-1 alpha precursor binds to the plasma membrane via a lectin-like interaction. J Immunol 143:1183–1187PubMed
33.
Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J et al (1992) Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 90:2333–2339PubMedPubMedCentralCrossRef
34.
35.
Piccioli P, Rubartelli A (2013) The secretion of IL-1beta and options for release. Semin Immunol 25:425–429PubMedCrossRef
36.
37.
Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426PubMedCrossRef
38.
Fantuzzi G, Ku G, Harding MW, Livingston DJ, Sipe JD, Kuida K et al (1997) Response to local inflammation of IL-1 beta-converting enzyme- deficient mice. J Immunol 158:1818–1824PubMed
39.
Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H et al (2009) Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 60:3651–3662PubMedPubMedCentralCrossRef
40.
Rubartelli A, Cozzolino F, Talio M, Sitia R (1990) A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J 9:1503–1510PubMedPubMedCentral
41.
Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A (1999) The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell 10:1463–1475PubMedPubMedCentralCrossRef
42.
Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A (2004) Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci U S A 101:9745–9750PubMedPubMedCentralCrossRef
43.
MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A (2001) Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15:825–835PubMedCrossRef
44.
Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M et al (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol 174:7268–7277PubMedCrossRef
45.
Qu Y, Franchi L, Nunez G, Dubyak GR (2007) Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol 179:1913–1925PubMedCrossRef
46.
47.
Eisenberg SP, Brewer MT, Verderber E, Heimdal P, Brandhuber BJ, Thompson RC (1991) Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A 88:5232–5236PubMedPubMedCentralCrossRef
48.
Palomo J, Dietrich D, Martin P, Palmer G, Gabay C (2015) The interleukin (IL)-1 cytokine family - Balance between agonists and antagonists in inflammatory diseases. Cytokine 76:25–37PubMedCrossRef
49.
Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP (1991) Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 266:10331–10336PubMed
50.
Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A et al (1997) A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386:194–200PubMedCrossRef
51.
McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL et al (1991) A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 10:2821–2832PubMedPubMedCentral
52.
Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF (2007) Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem 282:11982–11995PubMedCrossRef
53.
Symons JA, Young PR, Duff GW (1995) Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A 92:1714–1718PubMedPubMedCentralCrossRef
54.
Yamaki M, Sugiura K, Muro Y, Shimoyama Y, Tomita Y (2010) Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes. Exp Dermatol 19:730–735PubMedCrossRef
55.
Suwara MI, Green NJ, Borthwick LA, Mann J, Mayer-Barber KD, Barron L et al (2014) IL-1alpha released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts. Mucosal Immunol 7:684–693PubMedCrossRef
56.
Tracy EC, Bowman MJ, Henderson BW, Baumann H (2012) Interleukin-1alpha is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts. Br J Cancer 107:1534–1546PubMedPubMedCentralCrossRef
57.
Lindroos PM, Coin PG, Badgett A, Morgan DL, Bonner JC (1997) Alveolar macrophages stimulated with titanium dioxide, chrysotile asbestos, and residual oil fly ash upregulate the PDGF receptor-alpha on lung fibroblasts through an IL-1beta-dependent mechanism. Am J Respir Cell Mol Biol 16:283–292PubMedCrossRef
58.
Witowski J, Thiel A, Dechend R, Dunkel K, Fouquet N, Bender TO et al (2001) Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts: induction by macrophage-derived cytokines. Am J Pathol 158:1441–1450PubMedPubMedCentralCrossRef
59.
Postlethwaite AE, Raghow R, Stricklin GP, Poppleton H, Seyer JM, Kang AH (1988) Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol 106:311–318PubMedCrossRef
60.
Kahari VM, Heino J, Vuorio E (1987) Interleukin-1 increases collagen production and mRNA levels in cultured skin fibroblasts. Biochim Biophys Acta 929:142–147PubMedCrossRef
61.
Xiao H, Ji AM, Li ZL, Song XD, Su D, Chen AH (2008) Interleukin-1beta inhibits collagen synthesis and promotes its decomposition in cultured cardiac fibroblasts. Sheng Li Xue Bao 60:355–361PubMed
62.
Bhatnagar R, Penfornis H, Mauviel A, Loyau G, Saklatvala J, Pujol JP (1986) Interleukin-1 inhibits the synthesis of collagen by fibroblasts. Biochem Int 13:709–720PubMed
63.
Doerner AM, Zuraw BL (2009) TGF-beta1 induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells is enhanced by IL-1beta but not abrogated by corticosteroids. Respir Res 10:100PubMedPubMedCentralCrossRef
64.
Borthwick LA, McIlroy EI, Gorowiec MR, Brodlie M, Johnson GE, Ward C et al (2010) Inflammation and epithelial to mesenchymal transition in lung transplant recipients: role in dysregulated epithelial wound repair. Am J Transplant 10:498–509PubMedCrossRef
65.
Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J et al (2011) Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A 108:E1475–E1483PubMedPubMedCentralCrossRef
66.
Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M et al (2010) Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51:1027–1036PubMedPubMedCentralCrossRef
67.
Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J (2001) Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107:1529–1536PubMedPubMedCentralCrossRef
68.
Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S et al (2007) IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 117:3786–3799PubMedPubMedCentral
69.
Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW et al (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207:535–552PubMedPubMedCentralCrossRef
70.
Wilmott RW, Kitzmiller JA, Fiedler MA, Stark JM (1998) Generation of a transgenic mouse with lung-specific overexpression of the human interleukin-1 receptor antagonist protein. Am J Respir Cell Mol Biol 18:429–434PubMedCrossRef
71.
Mulrooney N, Jobe AH, Ikegami M (2004) Lung inflammatory responses to intratracheal interleukin-1alpha in ventilated preterm lambs. Pediatr Res 55:682–687PubMedCrossRef
72.
Hybertson BM, Jepson EK, Allard JD, Cho OJ, Lee YM, Huddleston JR et al (2003) Transforming growth factor beta contributes to lung leak in rats given interleukin-1 intratracheally. Exp Lung Res 29:361–373PubMedCrossRef
73.
Guo JL, Gu NL, Chen J, Shi TM, Zhou Y, Rong Y et al (2013) Neutralization of interleukin-1 beta attenuates silica-induced lung inflammation and fibrosis in C57BL/6 mice. Arch Toxicol 87:1963–1973PubMedCrossRef
74.
Ma Y, Thornton S, Boivin GP, Hirsh D, Hirsch R, Hirsch E (1998) Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 41:1798–1805PubMedCrossRef
75.
Piguet PF, Vesin C, Grau GE, Thompson RC (1993) Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 5:57–61PubMedCrossRef
76.
Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65:1006–1012PubMedPubMedCentralCrossRef
77.
Botelho FM, Bauer CM, Finch D, Nikota JK, Zavitz CC, Kelly A et al (2011) IL-1alpha/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One 6, e28457PubMedPubMedCentralCrossRef
78.
Gasse P, Riteau N, Charron S, Girre S, Fick L, Petrilli V et al (2009) Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care 179:903–913CrossRef
79.
Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL et al (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847–856PubMedPubMedCentralCrossRef
80.
Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674–677PubMedPubMedCentralCrossRef
81.
dos Santos G, Rogel MR, Baker MA, Troken JR, Urich D, Morales-Nebreda L et al (2015) Vimentin regulates activation of the NLRP3 inflammasome. Nat Commun 6:6574PubMedPubMedCentralCrossRef
82.
Sethi JM, Rochester CL (2000) Smoking and chronic obstructive pulmonary disease. Clin Chest Med 21:67–86, viiiPubMedCrossRef
83.
Kuschner WG, D’Alessandro A, Wong H, Blanc PD (1996) Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 9:1989–1994PubMedCrossRef
84.
Keatings VM, Collins PD, Scott DM, Barnes PJ (1996) Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153:530–534PubMedCrossRef
85.
Wanderer AA (2008) Interleukin-1beta targeted therapy in severe persistent asthma (SPA) and chronic obstructive pulmonary disease (COPD): proposed similarities between biphasic pathobiology of SPA/COPD and ischemia-reperfusion injury. Isr Med Assoc J 10:837–842PubMed
86.
Yigla M, Berkovich Y, Nagler RM (2007) Oxidative stress indices in COPD--Broncho-alveolar lavage and salivary analysis. Arch Oral Biol 52:36–43PubMedCrossRef
87.
Bartziokas K, Papaioannou AI, Loukides S, Papadopoulos A, Haniotou A, Papiris S et al (2014) Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J 43:43–53PubMedCrossRef
88.
Eltom S, Stevenson CS, Rastrick J, Dale N, Raemdonck K, Wong S et al (2011) P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS One 6, e24097PubMedPubMedCentralCrossRef
89.
Churg A, Zhou S, Wang X, Wang R, Wright JL (2009) The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol 40:482–490PubMedCrossRef
90.
91.
Lommatzsch M, Cicko S, Muller T, Lucattelli M, Bratke K, Stoll P et al (2010) Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:928–934PubMedCrossRef
92.
Cicko S, Lucattelli M, Muller T, Lommatzsch M, De Cunto G, Cardini S et al (2010) Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J Immunol 185:688–697PubMedCrossRef
93.
Barlo NP, van Moorsel CH, Korthagen NM, Heron M, Rijkers GT, Ruven HJ et al (2011) Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1beta in idiopathic pulmonary fibrosis. Clin Exp Immunol 166:346–351PubMedPubMedCentralCrossRef
94.
Ogushi F, Tani K, Endo T, Tada H, Kawano T, Asano T et al (2001) Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis. J Med Invest 48:181–189PubMed
95.
Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN (1993) Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 150:4188–4196PubMed
96.
Kline JN, Schwartz DA, Monick MM, Floerchinger CS, Hunninghake GW (1993) Relative release of interleukin-1 beta and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis. Chest 104:47–53PubMedCrossRef
97.
Lasithiotaki I, Giannarakis I, Tsitoura E, Samara KD, Margaritopoulos GA, Choulaki C et al (2016) NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung. Eur Respir J. doi:10.​1183/​13993003.​00564-2015 PubMed
98.
Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L et al (2010) Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 182:774–783PubMedCrossRef
99.
Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B (2014) Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349:209–220PubMedCrossRef
100.
Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A et al (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590:400–408PubMedCrossRef
101.
Belperio JA, DiGiovine B, Keane MP, Burdick MD, Ying Xue Y, Ross DJ et al (2002) Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation 73:591–599PubMedCrossRef
102.
Borthwick LA, Corris PA, Mahida R, Walker A, Gardner A, Suwara M et al (2013) TNFalpha from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis. Am J Transplant 13:621–633PubMedCrossRef
103.
Borthwick LA, Suwara MI, Carnell SC, Green NJ, Mahida R, Dixon D et al (2015) Pseudomonas aeruginosa induced airway epithelial injury drives fibroblast activation: a mechanism in chronic lung allograft dysfunction. Am J Transplant. doi:10.​1111/​ajt.​13690
104.
Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490PubMedCrossRef
105.
Baekkevold ES, Roussigne M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F et al (2003) Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163:69–79PubMedPubMedCentralCrossRef
106.
Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L et al (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 104:282–287PubMedCrossRef
107.
Roussel L, Erard M, Cayrol C, Girard JP (2008) Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 9:1006–1012PubMedPubMedCentralCrossRef
108.
Martin MU (2013) Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol 25:449–457PubMedCrossRef
109.
Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML et al (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 187:1609–1616PubMedCrossRef
110.
Lefrancais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP et al (2012) IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 109:1673–1678PubMedPubMedCentralCrossRef
111.
112.
Ali S, Nguyen DQ, Falk W, Martin MU (2010) Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun 391:1512–1516PubMedCrossRef
113.
Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C et al (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31:84–98PubMedCrossRef
114.
Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M (2012) Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol 132:2593–2600PubMedCrossRef
115.
Hayakawa M, Hayakawa H, Matsuyama Y, Tamemoto H, Okazaki H, Tominaga S (2009) Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun 387:218–222PubMedCrossRef
116.
Ali S, Hubert M, Kollewe C, Bischoff SC, Falk W, Martin MU (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 104:18660–18665PubMedPubMedCentralCrossRef
117.
Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551–2555PubMedCrossRef
118.
Hayakawa H, Hayakawa M, Kume A, Tominaga S (2007) Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282:26369–26380PubMedCrossRef
119.
Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T et al (2001) Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 285:1377–1383PubMedCrossRef
120.
Smith DE (2010) IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 40:200–208PubMedCrossRef
121.
Zhang L, Lu R, Zhao G, Pflugfelder SC, Li DQ (2011) TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol 43:1383–1391PubMedPubMedCentralCrossRef
122.
Polumuri SK, Jayakar GG, Shirey KA, Roberts ZJ, Perkins DJ, Pitha PM et al (2012) Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol 189:50–60PubMedPubMedCentralCrossRef
123.
Zhao WH, Hu ZQ (2012) Up-regulation of IL-33 expression in various types of murine cells by IL-3 and IL-4. Cytokine 58:267–273PubMedCrossRef
124.
Cayrol C, Girard JP (2014) IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 31:31–37PubMedCrossRef
125.
Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H et al (2010) Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463:540–544PubMedCrossRef
126.
Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK et al (2010) Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464:1367–1370PubMedPubMedCentralCrossRef
127.
Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ et al (2010) Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A 107:11489–11494PubMedPubMedCentralCrossRef
128.
Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA et al (2011) Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 12:1045–1054PubMedPubMedCentralCrossRef
129.
Kamijo S, Takeda H, Tokura T, Suzuki M, Inui K, Hara M et al (2013) IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol 190:4489–4499PubMed
130.
Besnard AG, Togbe D, Guillou N, Erard F, Quesniaux V, Ryffel B (2011) IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol 41:1675–1686PubMedCrossRef
131.
Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S et al (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183:6469–6477PubMedCrossRef
132.
133.
Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P (2015) Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 354:24–31PubMedCrossRef
134.
Li P, Ma H, Han D, Mou K (2015) Interleukin-33 affects cytokine production by keratinocytes in vitiligo. Clin Exp Dermatol 40:163–170PubMedCrossRef
135.
Kurokawa M, Matsukura S, Kawaguchi M, Ieki K, Suzuki S, Odaka M et al (2011) Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol 155(Suppl 1):12–20PubMedCrossRef
136.
137.
Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, Matsumoto K et al (2010) IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 185:5743–5750PubMedCrossRef
138.
Gao Q, Li Y, Li M (2015) The potential role of IL-33/ST2 signaling in fibrotic diseases. J Leukoc Biol 98:15–22PubMedCrossRef
139.
Luzina IG, Kopach P, Lockatell V, Kang PH, Nagarsekar A, Burke AP et al (2013) Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol 49:999–1008PubMedPubMedCentralCrossRef
140.
Gao Q, Li Y, Pan X, Yuan X, Peng X, Li M (2016) Lentivirus expressing soluble ST2 alleviates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol 30:188–193PubMedCrossRef
141.
Li D, Guabiraba R, Besnard AG, Komai-Koma M, Jabir MS, Zhang L et al (2014) IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol 134:1422–1432.e1411PubMedPubMedCentralCrossRef
142.
Luzina IG, Pickering EM, Kopach P, Kang PH, Lockatell V, Todd NW et al (2012) Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 189:403–410PubMedPubMedCentralCrossRef
143.
Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S (2011) Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 30:825–830PubMedCrossRef
144.
Qiu C, Li Y, Li M, Li M, Liu X, McSharry C et al (2013) Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice. Immunology 138:76–82PubMedCrossRef
145.
Wu H, Yang S, Wu X, Zhao J, Zhao J, Ning Q et al (2014) Interleukin-33/ST2 signaling promotes production of interleukin-6 and interleukin-8 in systemic inflammation in cigarette smoke-induced chronic obstructive pulmonary disease mice. Biochem Biophys Res Commun 450:110–116PubMedCrossRef
146.
Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N et al (2015) Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 42:566–579PubMedCrossRef
147.
Xia J, Zhao J, Shang J, Li M, Zeng Z, Zhao J et al (2015) Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 308:L619–L627PubMedCrossRef
148.
Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X et al (2013) Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123:3967–3982PubMedPubMedCentralCrossRef
149.
Shang J, Zhao J, Wu X, Xu Y, Xie J, Zhao J (2015) Interleukin-33 promotes inflammatory cytokine production in chronic airway inflammation. Biochem Cell Biol 93:359–366PubMedCrossRef
150.
Barnes PJ (2015) Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol 136:531–545PubMedCrossRef
151.
Wang X, Shannahan JH, Brown JM (2014) IL-33 modulates chronic airway resistance changes induced by multi-walled carbon nanotubes. Inhal Toxicol 26:240–249PubMedPubMedCentralCrossRef
152.
Tiringer K, Treis A, Kanolzer S, Witt C, Ghanim B, Gruber S et al (2014) Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients. Eur Respir J 44:802–805PubMedCrossRef
153.
Roussel L, Farias R, Rousseau S (2013) IL-33 is expressed in epithelia from patients with cystic fibrosis and potentiates neutrophil recruitment. J Allergy Clin Immunol 131:913–916PubMedCrossRef
154.
Okamura H, Nagata K, Komatsu T, Tanimoto T, Nukata Y, Tanabe F et al (1995) A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 63:3966–3972PubMedPubMedCentral
155.
Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA et al (1997) Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275:206–209PubMedCrossRef
156.
Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A et al (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386:619–623PubMedCrossRef
157.
158.
Morel JC, Park CC, Woods JM, Koch AE (2001) A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 276:37069–37075PubMedCrossRef
159.
Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA (2004) Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci U S A 101:8815–8820PubMedPubMedCentralCrossRef
160.
Novick D, Kim S, Kaplanski G, Dinarello CA (2013) Interleukin-18, more than a Th1 cytokine. Semin Immunol 25:439–448PubMedCrossRef
161.
Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M et al (2000) Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A 97:1190–1195PubMedPubMedCentralCrossRef
162.
Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M (1999) Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10:127–136PubMedCrossRef
163.
Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z et al (2001) A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14:334–342PubMedCrossRef
164.
Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12:53–72PubMedCrossRef
165.
Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M et al (1996) Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 26:1647–1651PubMedCrossRef
166.
Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB et al (2005) IL-18-induced CD83 + CCR7+ NK helper cells. J Exp Med 202:941–953PubMedPubMedCentralCrossRef
167.
Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G et al (2001) Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 281:R1264–R1273PubMed
168.
Sivakumar PV, Westrich GM, Kanaly S, Garka K, Born TL, Derry JM et al (2002) Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50:812–820PubMedPubMedCentralCrossRef
169.
Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S et al (2001) Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108:1825–1832PubMedPubMedCentralCrossRef
170.
Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY (2001) Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 166:517–521PubMedCrossRef
171.
Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT (2001) Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 166:959–965PubMedCrossRef
172.
Nakatani-Okuda A, Ueda H, Kashiwamura S, Sekiyama A, Kubota A, Fujita Y et al (2005) Protection against bleomycin-induced lung injury by IL-18 in mice. Am J Physiol Lung Cell Mol Physiol 289:L280–L287PubMedCrossRef
173.
Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H (2009) Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 41:661–670PubMedCrossRef
174.
Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S et al (2007) Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med 176:49–62PubMedCrossRef
175.
Kang MJ, Choi JM, Kim BH, Lee CM, Cho WK, Choe G et al (2012) IL-18 induces emphysema and airway and vascular remodeling via IFN-gamma, IL-17A, and IL-13. Am J Respir Crit Care Med 185:1205–1217PubMedPubMedCentralCrossRef
176.
Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ et al (2007) Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 56:1787–1797PubMedCrossRef
177.
Zhang W, Cong XL, Qin YH, He ZW, He DY, Dai SM (2013) IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis. Inflammation 36:103–109PubMedCrossRef
178.
Fix C, Bingham K, Carver W (2011) Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 53:19–28PubMedCrossRef
179.
Kitasato Y, Hoshino T, Okamoto M, Kato S, Koda Y, Nagata N et al (2004) Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 31:619–625PubMedCrossRef
180.
Kang MJ, Homer RJ, Gallo A, Lee CG, Crothers KA, Cho SJ et al (2007) IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation. J Immunol 178:1948–1959PubMedCrossRef
181.
Petersen AM, Penkowa M, Iversen M, Frydelund-Larsen L, Andersen JL, Mortensen J et al (2007) Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung 185:161–171PubMedCrossRef
182.
Wang J, Liu X, Xie M, Xie J, Xiong W, Xu Y (2012) Increased expression of interleukin-18 and its receptor in peripheral blood of patients with chronic obstructive pulmonary disease. COPD 9:375–381PubMedCrossRef
183.
Rovina N, Dima E, Gerassimou C, Kollintza A, Gratziou C, Roussos C (2009) Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease. Respir Med 103:1056–1062PubMedCrossRef
184.
Imaoka H, Hoshino T, Takei S, Kinoshita T, Okamoto M, Kawayama T et al (2008) Interleukin-18 production and pulmonary function in COPD. Eur Respir J 31:287–297PubMedCrossRef
185.
Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D et al (2011) IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 22:127–147PubMed
186.
Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE (2000) Four new members expand the interleukin-1 superfamily. J Biol Chem 275:1169–1175PubMedCrossRef
187.
Busfield SJ, Comrack CA, Yu G, Chickering TW, Smutko JS, Zhou H et al (2000) Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 66:213–216PubMedCrossRef
188.
Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE et al (2000) Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 275:10308–10314PubMedCrossRef
189.
Kumar S, Hanning CR, Brigham-Burke MR, Rieman DJ, Lehr R, Khandekar S et al (2002) Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 18:61–71PubMedCrossRef
190.
Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E et al (2001) IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 13:1–7PubMedCrossRef
191.
Bufler P, Azam T, Gamboni-Robertson F, Reznikov LL, Kumar S, Dinarello CA et al (2002) A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A 99:13723–13728PubMedPubMedCentralCrossRef
192.
Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP et al (2015) IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol 16:354–365PubMedCrossRef
193.
Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014–1022PubMedPubMedCentralCrossRef
194.
Sharma S, Kulk N, Nold MF, Graf R, Kim SH, Reinhardt D et al (2008) The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 180:5477–5482PubMedCrossRef
195.
Grimsby S, Jaensson H, Dubrovska A, Lomnytska M, Hellman U, Souchelnytskyi S (2004) Proteomics-based identification of proteins interacting with Smad3: SREBP-2 forms a complex with Smad3 and inhibits its transcriptional activity. FEBS Lett 577:93–100PubMedCrossRef
196.
Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S (2004) A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J 18:161–163PubMed
197.
McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB et al (2011) Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 108:16711–16716PubMedPubMedCentralCrossRef
198.
Luo Y, Cai X, Liu S, Wang S, Nold-Petry CA, Nold MF et al (2014) Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A 111:15178–15183PubMedPubMedCentralCrossRef
199.
200.
Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, Blanchard J et al (2012) Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 27:1609–1616PubMedPubMedCentralCrossRef
201.
Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, Iannitti RG et al (2014) IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog 10, e1004462PubMedPubMedCentralCrossRef
202.
203.
Raedler D, Ballenberger N, Klucker E, Bock A, Otto R, Prazeres da Costa O et al (2015) Identification of novel immune phenotypes for allergic and nonallergic childhood asthma. J Allergy Clin Immunol 135:81–91PubMedCrossRef
204.
Charrad R, Berraies A, Hamdi B, Ammar J, Hamzaoui K, Hamzaoui A (2016) Anti-inflammatory activity of IL-37 in asthmatic children: correlation with inflammatory cytokines TNF-alpha, IL-beta, IL-6 and IL-17A. Immunobiology 221(2):182–187. doi:10.​1016/​j.​imbio.​2015.​09.​009.
205.
Lunding L, Webering S, Vock C, Schroder A, Raedler D, Schaub B et al (2015) IL-37 requires IL-18Ralpha and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy 70:366–373PubMedCrossRef
206.
Zhang J, Liu G, Zeng J, Wang W, Xiang W, Kong B et al (2015) Clinical detection and significance of plasma IL-37 in patients with active pulmonary tuberculosis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 31:520–523PubMed
207.
Huang Z, Gao C, Chi X, Hu YW, Zheng L, Zeng T et al (2015) IL-37 expression is upregulated in patients with tuberculosis and induces macrophages towards an M2-like phenotype. Scand J Immunol 82:370–379PubMedCrossRef
208.
Di Stefano A, Caramori G, Barczyk A, Vicari C, Brun P, Zanini A et al (2014) Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax 69:516–524PubMedPubMedCentralCrossRef
209.
210.
Abbatt JD, Lea AJ (1956) The incidence of leukaemia in ankylosing spondylitis treated with x-rays. Lancet 271:1317–1320PubMedCrossRef
211.
Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA et al (2011) Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 286:42594–42602PubMedPubMedCentralCrossRef
212.
Martin U, Scholler J, Gurgel J, Renshaw B, Sims JE, Gabel CA (2009) Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophages. J Immunol 183:4021–4030PubMedCrossRef
213.
Gresnigt MS, van de Veerdonk FL (2013) Biology of IL-36 cytokines and their role in disease. Semin Immunol 25:458–465PubMedCrossRef
214.
Li Y, Messina C, Bendaoud M, Fine DH, Schreiner H, Tsiagbe VK (2010) Adaptive immune response in osteoclastic bone resorption induced by orally administered Aggregatibacter actinomycetemcomitans in a rat model of periodontal disease. Mol Oral Microbiol 25:275–292PubMedCrossRef
215.
Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E et al (2011) IL-36R ligands are potent regulators of dendritic and T cells. Blood 118:5813–5823PubMedCrossRef
216.
Turtoi A, Brown I, Schlager M, Schneeweiss FH (2010) Gene expression profile of human lymphocytes exposed to (211)At alpha particles. Radiat Res 174:125–136PubMedCrossRef
217.
Yang J, Meyer M, Muller AK, Bohm F, Grose R, Dauwalder T et al (2010) Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J Cell Biol 188:935–952PubMedPubMedCentralCrossRef
218.
Debets R, Timans JC, Homey B, Zurawski S, Sana TR, Lo S et al (2001) Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol 167:1440–1446PubMedCrossRef
219.
Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 279:13677–13688PubMedCrossRef
220.
Vigne S, Palmer G, Martin P, Lamacchia C, Strebel D, Rodriguez E et al (2012) IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood 120:3478–3487PubMedCrossRef
221.
Chustz RT, Nagarkar DR, Poposki JA, Favoreto S Jr, Avila PC, Schleimer RP et al (2011) Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am J Respir Cell Mol Biol 45:145–153PubMedCrossRef
222.
Bochkov YA, Hanson KM, Keles S, Brockman-Schneider RA, Jarjour NN, Gern JE (2010) Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol 3:69–80PubMedCrossRef
223.
Vos JB, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS, Datson NA (2005) Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol Genomics 21:324–336PubMedCrossRef
224.
Ramadas RA, Ewart SL, Medoff BD, LeVine AM (2011) Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol 44:134–145PubMedCrossRef
225.
226.
Gabay C, Towne JE (2015) Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol 97:645–652PubMedCrossRef
227.
Parsanejad R, Fields WR, Steichen TJ, Bombick BR, Doolittle DJ (2008) Distinct regulatory profiles of interleukins and chemokines in response to cigarette smoke condensate in normal human bronchial epithelial (NHBE) cells. J Interferon Cytokine Res 28:703–712PubMedCrossRef
228.
Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, Bas S et al (2006) The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 8:R80PubMedPubMedCentralCrossRef
229.
Derer A, Groetsch B, Harre U, Bohm C, Towne J, Schett G et al (2014) Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis. PLoS One 9, e101954PubMedPubMedCentralCrossRef
230.
DeVoti JA, Rosenthal DW, Wu R, Abramson AL, Steinberg BM, Bonagura VR (2008) Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis. Mol Med 14:608–617PubMedPubMedCentralCrossRef
231.
Chen H, Wang Y, Bai C, Wang X (2012) Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. J Proteomics 75:2835–2843PubMedCrossRef
232.
Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM et al (2001) Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 276:20597–20602PubMedCrossRef
233.
Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW (2001) Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J Interferon Cytokine Res 21:899–904PubMedCrossRef
234.
Nicklin MJ, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K (2002) A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics 79:718–725PubMedCrossRef
235.
Ciccia F, Accardo-Palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G et al (2015) Interleukin-36alpha axis is modulated in patients with primary Sjogren’s syndrome. Clin Exp Immunol 181:230–238PubMedPubMedCentralCrossRef
236.
van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG et al (2012) IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 109:3001–3005PubMedPubMedCentralCrossRef
237.
Monnet D, Kadi A, Izac B, Lebrun N, Letourneur F, Zinovieva E et al (2012) Association between the IL-1 family gene cluster and spondyloarthritis. Ann Rheum Dis 71:885–890PubMedCrossRef
238.
Lea WI, Lee YH (2012) The associations between interleukin-1 polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis. Jt Bone Spine 79:370–374CrossRef
239.
Yuan X, Peng X, Li Y, Li M (2015) Role of IL-38 and its related cytokines in inflammation. Mediat Inflamm 2015:807976CrossRef
240.
Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L et al (2013) Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 15:R123PubMedPubMedCentralCrossRef
241.
Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652PubMedPubMedCentralCrossRef
242.
Brusselle GG, Provoost S, Bracke KR, Kuchmiy A, Lamkanfi M (2014) Inflammasomes in respiratory disease: from bench to bedside. Chest 145:1121–1133PubMedCrossRef
243.
Haycock JW (2011) 3D cell culture: a review of current approaches and techniques. Methods Mol Biol 695:1–15PubMedCrossRef
244.
Morin JP, Baste JM, Gay A, Crochemore C, Corbiere C, Monteil C (2013) Precision cut lung slices as an efficient tool for in vitro lung physio-pharmacotoxicology studies. Xenobiotica 43:63–72PubMedCrossRef
245.
Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M et al (2001) Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 24:591–598PubMedCrossRef
246.
Emblom-Callahan MC, Chhina MK, Shlobin OA, Ahmad S, Reese ES, Iyer EP et al (2010) Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics 96:134–145PubMedCrossRef
247.
Huang SK, Scruggs AM, McEachin RC, White ES, Peters-Golden M (2014) Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS One 9, e107055PubMedPubMedCentralCrossRef
248.
Liu X, Sun SQ, Ostrom RS (2005) Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient cAMP response element-binding protein phosphorylation. J Pharmacol Exp Ther 315:678–687PubMedCrossRef
Metadata
Title
The IL-1 cytokine family and its role in inflammation and fibrosis in the lung
Author
L. A. Borthwick
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 4/2016
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-016-0559-z

Other articles of this Issue 4/2016

Seminars in Immunopathology 4/2016 Go to the issue

Review

The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation

Review

COPD immunopathology

Review Article

Type 2 innate lymphoid cells: at the cross-roads in allergic asthma

Introduction

Immunopathology of lung diseases: introduction for the special issue

Review

Key mechanisms governing resolution of lung inflammation

Review

Dendritic cells in lung immunopathology
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits